← All trials
NCT05855187
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Nov 22, 2022
- Completion date
- Jan 10, 2023
- First posted
- May 11, 2023
- Last posted
- May 11, 2023
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Genuine Research Center, EgyptLead sponsor
- Genuine Research Center, EgyptStudy director
- Genuine Research Center, EgyptOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.